Management of Hyponatremia in Cirrhosis

Management of Hyponatremia in Cirrhosis

Comprehensive Summary of CME Lecture by Dr. Adrià Juanola, MD, PhD

1. Main Clinical Topics Discussed

• Pathophysiology of ascites and hyponatremia in decompensated cirrhosis
• Classification and differential diagnosis of hyponatremia in cirrhotic patients
• Clinical impact and prognostic significance of hyponatremia
• Management strategies, including emerging evidence from the ALBUKA trial

2. Pathophysiology: Key Learning Points

Portal Hypertension Cascade

• Cirrhosis causes structural disruption (regenerative nodules) and increased hepatic vascular tone → portal hypertension
• Splanchnic vasodilation (mediated by nitric oxide, carbon monoxide, endocannabinoids) → reduced effective arterial blood volume
• Compensatory neurohormonal activation ensues:

- Renin-angiotensin-aldosterone system (RAAS) → sodium retention → ascites

- Sympathetic nervous system → peripheral vasoconstriction → hepatorenal syndrome risk

- Arginine vasopressin (AVP) → solute-free water retention → dilutional hyponatremia

Vasopressin and Copeptin

• AVP binds V2 receptors on renal collecting duct cells → activates adenylyl cyclase → upregulates aquaporin-2 → free water reabsorption → dilutional hyponatremia
• AVP is difficult to measure directly; copeptin (co-synthesized from the same gene precursor) serves as a validated surrogate biomarker
• Published data demonstrate copeptin levels:

- Positively correlate with plasma renin activity, aldosterone, and noradrenaline

- Inversely correlate with serum sodium

- Are significantly elevated in patients with hyponatremia vs. those without

3. Classification of Hyponatremia in Cirrhosis

• Key diagnostic criterion: Hypervolemic hyponatremia requires the presence of ascites and/or peripheral edema
• Hepatic encephalopathy may be a variable associated feature

4. Clinical Data and Statistics Cited

• Prevalence of hyponatremia in decompensated cirrhosis (Angeli et al., Padova):

- ~20–25% of patients if threshold set at Na⁺ < 130 mEq/L

- Up to 50% of patients if threshold set at Na⁺ < 135 mEq/L

• Mortality risk (Kim et al., *New England Journal of Medicine*, 2008):

- Patients with serum sodium 130–135 mEq/L demonstrated elevated relative risk of death compared to those with higher sodium levels

- Underscores clinical relevance of the 130–135 mEq/L range, not only frank hyponatremia (<130 mEq/L)

• Neurohormonal activation (historical data, >30 years old):

- Plasma renin activity, aldosterone, and norepinephrine progressively increase from healthy subjects → compensated cirrhosis → decompensated cirrhosis

- Higher aldosterone levels associated with reduced urinary sodium excretion, driving ascites formation

• ALBUKA Trial (multicenter, randomized):

- Short-term intravenous albumin administration in hospitalized cirrhotic patients with dilutional hyponatremia

- Demonstrated **improvement in serum sodium